Published in Cancer Cell on March 13, 2017
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med (2017) 1.17
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med (2017) 1.16
AP4 modulated by the PI3K/AKT pathway promotes prostate cancer proliferation and metastasis of prostate cancer via upregulating L-plastin. Cell Death Dis (2017) 0.75
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature (1997) 11.15
STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res (2014) 10.79
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29
2016 update of the PRIDE database and its related tools. Nucleic Acids Res (2015) 5.14
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev (1998) 3.79
Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci (2005) 3.77
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell (2004) 3.46
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer (2009) 3.33
The Molecular Taxonomy of Primary Prostate Cancer. Cell (2015) 3.29
Organoid cultures derived from patients with advanced prostate cancer. Cell (2014) 3.12
Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell (2014) 3.05
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell (2016) 2.26
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med (2013) 2.26
The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell (2009) 2.07
Isolation, cultivation and characterization of adult murine prostate stem cells. Nat Protoc (2010) 1.96
ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev (2013) 1.87
Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol (2014) 1.84
Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep (2014) 1.68
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A (2013) 1.66
Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science (2014) 1.45
p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res (2002) 1.29
SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Mol Cell (2015) 1.25
SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia (2014) 1.23
Single luminal epithelial progenitors can generate prostate organoids in culture. Nat Cell Biol (2014) 1.19
Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. Mol Cell (2015) 1.17
Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther (2013) 1.12
SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell (2014) 1.11
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res (2014) 1.07
DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell (2015) 1.04
Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am J Pathol (2011) 1.01
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov (2014) 1.01
SPOP mutation leads to genomic instability in prostate cancer. Elife (2015) 0.93
Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells. J Biol Chem (2014) 0.87
The lethal clone in prostate cancer: redefining the index. Eur Urol (2014) 0.79
Multiple Weak Linear Motifs Enhance Recruitment and Processivity in SPOP-Mediated Substrate Ubiquitination. J Mol Biol (2015) 0.79
A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. PLoS One (2016) 0.77